RNA
Atrium Therapeutics, Inc. Common Stock
$13.07
+0.85%
2026-05-08
About Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Key Fundamentals
Forward P/E
-3.19
EPS (TTM)
$-4.48
ROE
-44.0%
Revenue Growth (YoY)
-71.1%
Profit Margin
-265.9%
Debt/Equity
2.92
Price/Book
6.52
Beta
0.93
Market Cap
$199.8M
Avg Volume (10D)
245K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$73.05
60D Low
$11.95
Avg Volume
1.2M
Latest Close
$13.07
Get breakout alerts for RNA
Sign up for Breakout Scanner to receive daily notifications when RNA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Atrium Therapeutics, Inc. Common Stock (RNA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors RNA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. RNA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.